BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22339090)

  • 1. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
    Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
    J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins.
    Ashoorzadeh A; Atwell GJ; Pruijn FB; Wilson WR; Tercel M; Denny WA; Stevenson RJ
    Bioorg Med Chem; 2011 Aug; 19(16):4851-60. PubMed ID: 21767954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
    Stevenson RJ; Denny WA; Ashoorzadeh A; Pruijn FB; van Leeuwen WF; Tercel M
    Bioorg Med Chem; 2011 Oct; 19(20):5989-98. PubMed ID: 21920763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
    Tercel M; Yang S; Atwell GJ; Smith E; Gu Y; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    Bioorg Med Chem; 2010 Jul; 18(14):4997-5006. PubMed ID: 20580559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and antitumour properties of the enantiomers of a hypoxia-selective nitro analogue of the duocarmycins.
    Tercel M; Lee HH; Yang S; Liyanage HD; Mehta SY; Boyd PD; Jaiswal JK; Tan KL; Pruijn FB
    ChemMedChem; 2011 Oct; 6(10):1860-71. PubMed ID: 21793220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
    Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
    J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits.
    Atwell GJ; Milbank JJ; Wilson WR; Hogg A; Denny WA
    J Med Chem; 1999 Aug; 42(17):3400-11. PubMed ID: 10464026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins.
    Milbank JB; Stevenson RJ; Ware DC; Chang JY; Tercel M; Ahn GO; Wilson WR; Denny WA
    J Med Chem; 2009 Nov; 52(21):6822-34. PubMed ID: 19821576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity.
    Milbank JB; Tercel M; Atwell GJ; Wilson WR; Hogg A; Denny WA
    J Med Chem; 1999 Feb; 42(4):649-58. PubMed ID: 10052972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs.
    Lu GL; Stevenson RJ; Chang JY; Brothers PJ; Ware DC; Wilson WR; Denny WA; Tercel M
    Bioorg Med Chem; 2011 Aug; 19(16):4861-7. PubMed ID: 21775153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
    Sato A; McNulty L; Cox K; Kim S; Scott A; Daniell K; Summerville K; Price C; Hudson S; Kiakos K; Hartley JA; Asao T; Lee M
    J Med Chem; 2005 Jun; 48(11):3903-18. PubMed ID: 15916443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
    J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
    Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
    Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
    Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
    J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.
    Lajiness JP; Robertson WM; Dunwiddie I; Broward MA; Vielhauer GA; Weir SJ; Boger DL
    J Med Chem; 2010 Nov; 53(21):7731-8. PubMed ID: 20942408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
    Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
    Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.